<DOC>
	<DOCNO>NCT01434459</DOCNO>
	<brief_summary>Therasphere form treatment design selectively deliver radiation cancer within patient 's liver . This form treatment use number clinical trial approve use treatment liver cancer . The investigator want test safety use Gemcitabine ( chemotherapy drug ) TheraSphere ( radioactive bead inject directly blood vessel supply tumor liver ) patient advance pancreatobiliary tumor pancreatic cancer cholangiocarcinoma ( bile duct tumor ) involve liver .</brief_summary>
	<brief_title>Study Gemcitabine With TheraSphere® ( Yttrium-90 ) Patients With Hepatic Tumors Pancreatobiliary Origin</brief_title>
	<detailed_description>Patients liver predominant cholangiocarcinoma pancreatic cancer consider trial . The patient wre treat group thre patient . Each three patient receive pre-specified dose gemcitabine full dose radioembolization use theraspheres . If significant side effect observe three additional three patient treat high dose gemcitabine . The purpose identify high dose gemcitabine safely combined theraspheres .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Histologic cytologic diagnosis pancreatic cancer cholangiocarcinoma 2 . Liver predominant disease define Cholangiocarcinoma : liver disease unresectable Limited extra hepatic metastasis define : . Lung metastasis : 6 less nodule nodule great 1.5 cm . ii . Abdominal lymph node iii . Pancreatic primary long size le 4 cm size iv . Bone metastasis 3 . No prior systemic therapy advance stage disease 4 . Measurable target tumor use standard image technique 5 . Lung shunt less 20 % 6 . ECOG performance status 01 ( See Appendix ) 7 . Age ≥ 18 year 8 . No investigational agent protocol 9 . Signed informed consent 1 . Inadequate hepatic function : AST/ALT &gt; five time upper limit normal , Bilirubin &gt; 2.0 mg/dl history hepatic encephalopathy 2 . Inadequate renal function Creatinine &gt; 2.0 mg/dL 3 . Inadequate bone marrow function : platelet &lt; 100,000/mL absolute neutrophil count &lt; 1500/mL 4 . Contraindication angiography 5 . Prior external beam radiotherapy upper abdomen 6 . Clinical evidence peritoneal metastasis ascites 7 . Patients extensive tumor replacement liver define &gt; 50 % liver involved tumor 8 . Any serious ongoing extrahepatic disease infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Pancreatic neoplasm</keyword>
	<keyword>Cholangiocarcinoma</keyword>
</DOC>